

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT CNGT AND GERMAN ITM COMPANY ENTERED INTO A JOINT VENTURE COOPERATION AGREEMENT

This announcement is made by China Isotope & Radiation Corporation (the “**Company**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company.

The Board of Directors (the “**Board**”) of the Company is pleased to announce that, Chengdu Gaotong Isotope Co., Ltd., a subsidiary of CIRC, entered into a joint venture cooperation agreement with German ITM Company (ITM Isotopen Technologien München AG), marking the forthcoming establishment of the first Sino-German joint venture committed to the domestic supply of a new generation of integrated medical isotopes for diagnosis and treatment.

CNGT is a holding subsidiary of China Isotope & Radiation Corporation. CNGT focuses on the development, production and sales of radioisotope products, and also engages in import and export trade and cargo transportation.

ITM is a corporation organized under the laws of Germany and is a wholly owned subsidiary of ITM Isotopen Technologien München AG, a company dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals in precision oncology.

The Sino-German joint venture was formed based on the 68Ge-68Ga generator and no-carrier added (n.c.a) Lu-177 (EndolucinBeta) production and sales technology licensing agreement signed by both parties in 2019, which is another significant milestone in the overall progress of the technology transfer project. It is a further deepening cooperation between CIRC and German ITM Company in the field of medical isotopes and the application and promotion of the new generation of integrated drugs for diagnosis and treatment, which will accelerate the provision of new radionuclides and services based on patented technologies and internationally recognized quality standards for the Chinese market. The joint venture will provide high-quality and economically sustainable treatment solutions for cancer patients in China and promote the development of nuclear medicine and national health in China.

This transaction does not constitute a notifiable transaction under Chapter 14 and a connected transaction under Chapter 14A of the Hong Kong Listing Rules.

By order of the Board
China Isotope & Radiation Corporation
Chairman
Meng Yanbin

Beijing, the PRC, 13 September 2021

As at the date of this announcement, the Board comprises Mr. Meng Yanbin, Mr. Wang Suohui and Mr. Du Jin as executive Directors; Mr. Liu Zhonglin, Mr. Chen Shoulei, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Hui Wan Fai, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.